Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals

Journal of Infectious Diseases

Volumn 211, Issue 7, 2015, Pages 1076-1086

  Hodgson, Susanne H ^a   Ewer, Katie J ^a   Bliss, Carly M ^a   Edwards, Nick J ^a   Rampling, Thomas ^a   Anagnostou, Nicholas A ^a   De Barra, Eoghan ^a,f   Havelock, Tom ^d   Bowyer, Georgina ^a   Poulton, Ian D ^a   De Cassan, Simone ^a   Longley, Rhea ^a   Illingworth, Joseph J ^a   Douglas, Alexander D ^a   Mange, Pooja B ^a   Collins, Katharine A ^a   Roberts, Rachel ^a   Gerry, Stephen ^b   Berrie, Eleanor ^c   Moyle, Sarah ^c   Colloca, Stefano ^g   Cortese, Riccardo ^j   Sinden, Robert E ^a,e   Gilbert, Sarah C ^a   Bejon, Philip ^k   Lawrie, Alison M ^a   Nicosia, Alfredo ^g,h,i   Faust, Saul N ^d   Hill, Adrian V S ^a   more..

^a UK   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^g Okairos ^*  (Italy)

^h CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

ⁱ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^j Okairos AG   (Switzerland)

^k KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

more..

Author keywords

ChAd63; CHMI; CS; malaria; ME TRAP; MVA; P. falciparum; vaccine

Indexed keywords

ADENOVIRUS VECTOR; CIRCUMSPOROZOITE PROTEIN; MALARIA VACCINE; MULTIPLE EPITOPE THROMBOSPONDIN RELATED ADHESION PROTEIN; POXVIRUS VECTOR; UNCLASSIFIED DRUG; CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; EPITOPE; GAMMA INTERFERON; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY; THROMBOSPONDIN-RELATED ADHESIVE PROTEIN, PROTOZOAN;

ADULT; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INFECTION PREVENTION; LIVER; MALARIA FALCIPARUM; MALE; MIDDLE AGED; OPEN STUDY; PARASITE LOAD; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SIMIAN VIRUS; SIMIAN VIRUS 63; YOUNG ADULT; ADOLESCENT; BIOSYNTHESIS; CLINICAL TRIAL; GENE VECTOR; GENETICS; IMMUNOLOGY; MALARIA, FALCIPARUM; PARASITOLOGY; PLASMODIUM FALCIPARUM; VIROLOGY;

ADENOVIRUSES, SIMIAN; ADOLESCENT; ADULT; ANTIBODIES, PROTOZOAN; EPITOPES; FEMALE; GENETIC VECTORS; HUMANS; INTERFERON-GAMMA; LIVER; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; YOUNG ADULT;

EID: 84927729727     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu579     Document Type: Conference Paper

References (42)

1. White NJ, Pukrittayakamee S, Hien TT, et al. Malaria. Lancet 2014; 383:723-35.
2. WHO. World Malaria Report 2013.
3. Agnandji ST, Lell B, Fernandes JF, et al. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N Engl J Med 2012; 367:2284-95.
4. Olotu A, Fegan G, Wambua J, et al. Four-year efficacy of RTS, S/AS01E and its interaction with malaria exposure. N Engl J Med 2013; 368: 1111-20.
5. Bejon P, White MT, Olotu A, et al. Efficacy of RTS, S malaria vaccines: individual-participant pooled analysis of phase 2 data. Lancet Infect Dis 2013; 13:319-27.
6. Agnandji ST, Fendel R, Mestre M, et al. Induction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS, S/AS01(E) and RTS, S/AS02(D). PLoS One 2011; 6:e18559.
7. Foquet L, Hermsen CC, van Gemert GJ, et al. Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection. J Clin Invest 2014; 124:140-4.
8. Ndungu FM, Mwacharo J, Kimani D, et al. A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS, S/AS01E. PLoS One 2012; 7:e52870.
9. Birkett AJ, Moorthy VS, Loucq C, Chitnis CE, Kaslow DC. Malaria vaccine R&D in the Decade of Vaccines: breakthroughs, challenges and opportunities. Vaccine 2013; 31(suppl 2):B233-43.
10. WHO. Malaria Vaccine Technology Roadmap 2013.
11. Sedegah M, Hollingdale MR, Farooq F, et al. Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes. PLoS One 2014; 9:e106241.
12. Schwenk RJ, Richie TL. Protective immunity to pre-erythrocytic stage malaria. Trends Parasitol 2011; 27:306-14.
13. Hoffman SL, Isenbarger D, Long GW, et al. Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. Science 1989; 244:1078-81.
14. Khusmith S, Sedegah M, Hoffman SL. Complete protection against Plasmodium yoelii by adoptive transfer of a CD8+ cytotoxic T-cell clone recognizing sporozoite surface protein 2. Infect Immun 1994; 62:2979-83.
15. Romero P, Maryanski JL, Corradin G, et al. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 1989; 341:323-6.
16. Weiss WR, Mellouk S, Houghten RA, et al. Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. J Exp Med 1990; 171:763-73.
17. Ewer KJ, O'Hara GA, Duncan CJ, et al. Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 2013; 4:2836.
18. Hill AV, Reyes-Sandoval A, O'Hara G, et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin 2010; 6:78-83.
19. Chuang I, SedegahM, Cicatelli S, et al. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One 2013; 8:e55571.
20. Tamminga C, Sedegah M, Maiolatesi S, et al. Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection. Hum Vaccin Immunother 2013; 9:2165-77.
21. Reyes-Sandoval A, Berthoud T, Alder N, et al. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 2010; 78:145-53.
22. Colloca S, Barnes E, Folgori A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012; 4:115ra112.
23. Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol 2011; 11:57-64.
24. Thompson FM, Porter DW, Okitsu SL, et al. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS One 2008; 3:e1493.
25. O'Hara GA, Duncan CJ, Ewer KJ, et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 2012; 205:772-81.
26. Dunachie SJ, Walther M, Epstein JE, et al. A DNA prime-modified vaccinia virus Ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun 2006; 74:5933-42.
27. Walther M, Thompson FM, Dunachie S, et al. Safety, immunogenicity, and efficacy of prime-boost immunizationwith recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein. Infect Immun 2006; 74:2706-16.
28. Imoukhuede EB, Berthoud T, Milligan P, et al. Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men. Vaccine 2006; 24:6526-33.
29. Bejon P, Peshu N, Gilbert SC, et al. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya. Clin Infect Dis 2006; 42:1102-10.
30. Bruna-Romero O, Rocha CD, Tsuji M, Gazzinelli RT. Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif. Vaccine 2004; 22:3575-84.
31. Coppi A, Pinzon-Ortiz C, Hutter C, Sinnis P. The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion. J Exp Med 2005; 201:27-33.
32. Singh AP, Buscaglia CA, Wang Q, et al. Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite. Cell 2007; 131:492-504.
33. Cottingham MG, Carroll F, Morris SJ, et al. Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors. Biotechnol Bioeng 2012; 109:719-28.
34. Epstein JE, Tewari K, Lyke KE, et al. Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science 2011; 334:475-80.
35. Sheehy SH, Duncan CJ, Elias SC, et al. ChAd63-MVA-vectored bloodstage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther 2012; 20:2355-68.
36. Bejon P, Andrews L, Andersen RF, et al. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J Infect Dis 2005; 191:619-26.
37. Sheehy SH, Duncan CJ, Elias SC, et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 2011; 19:2269-76.
38. Sheehy SH, Duncan CJ, Elias SC, et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVAvaccine vectors. PLoS One 2012; 7: e31208.
39. Sedegah M, Kim Y, Ganeshan H, et al. Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP). Malar J 2013; 12:185.
40. Epstein JE, Rao S, Williams F, et al. Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J Infect Dis 2007; 196:145-54.
41. Kester KE, Cummings JF, Ofori-Anyinam O, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009; 200:337-46.
42. Webster DP, Dunachie S, Vuola JM, et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci USA 2005; 102:4836-41.